Munich Reinsurance Co Stock Corp in Munich decreased its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 3.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 190,264 shares of the company's stock after selling 6,273 shares during the period. Elevance Health makes up about 1.6% of Munich Reinsurance Co Stock Corp in Munich's investment portfolio, making the stock its 20th largest holding. Munich Reinsurance Co Stock Corp in Munich owned about 0.09% of Elevance Health worth $66,364,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in the stock. Sound View Wealth Advisors Group LLC lifted its position in Elevance Health by 3.0% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company's stock valued at $354,000 after acquiring an additional 29 shares in the last quarter. Perigon Wealth Management LLC lifted its position in Elevance Health by 2.2% in the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company's stock valued at $481,000 after acquiring an additional 29 shares in the last quarter. Fulton Breakefield Broenniman LLC lifted its position in Elevance Health by 3.6% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company's stock valued at $289,000 after acquiring an additional 29 shares in the last quarter. Savvy Advisors Inc. lifted its position in Elevance Health by 3.2% in the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company's stock valued at $343,000 after acquiring an additional 30 shares in the last quarter. Finally, HBK Sorce Advisory LLC lifted its position in Elevance Health by 4.4% in the 3rd quarter. HBK Sorce Advisory LLC now owns 743 shares of the company's stock valued at $260,000 after acquiring an additional 31 shares in the last quarter. 89.24% of the stock is owned by institutional investors.
Elevance Health Stock Performance
Shares of ELV stock opened at $344.64 on Friday. The company has a market capitalization of $74.84 billion, a price-to-earnings ratio of 14.66, a PEG ratio of 1.84 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.48. The company has a 50-day simple moving average of $308.96 and a 200 day simple moving average of $331.62. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $427.54.
Elevance Health (NYSE:ELV - Get Free Report) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health's revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, sell-side analysts predict that Elevance Health, Inc. will post 26.79 earnings per share for the current year.
Elevance Health Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. Elevance Health's payout ratio is presently 27.39%.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on ELV shares. Royal Bank Of Canada downgraded shares of Elevance Health from an "outperform" rating to a "sector perform" rating and set a $358.00 target price for the company. in a research report on Tuesday, February 3rd. Truist Financial reduced their price objective on shares of Elevance Health from $390.00 to $375.00 and set a "buy" rating for the company in a research note on Monday, April 13th. Barclays increased their price objective on shares of Elevance Health from $393.00 to $408.00 and gave the stock an "overweight" rating in a research note on Friday. Mizuho reduced their price objective on shares of Elevance Health from $413.00 to $350.00 and set an "outperform" rating for the company in a research note on Wednesday, March 11th. Finally, Leerink Partners set a $364.00 price objective on shares of Elevance Health in a research note on Thursday. Eleven equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $380.42.
Read Our Latest Research Report on ELV
Elevance Health News Roundup
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
- Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an "outperform" rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
- Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
- Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
- Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
- Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
- Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
- Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird's update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT
Elevance Health Profile
(
Free Report)
Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.
Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
